亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

医学 瑞戈非尼 无容量 结直肠癌 内科学 打开标签 癌症 肿瘤科 临床试验 免疫疗法
作者
Shota Fukuoka,Hiroki Hara,Naoki Takahashi,Takashi Kojima,Akihito Kawazoe,Masako Asayama,Takako Yoshii,Daisuke Kotani,Hitomi Tamura,Yuichi Mikamoto,Nami Hirano,Masashi Wakabayashi,Shogo Nomura,Akihiro Sato,Takeshi Kuwata,Yosuke Togashi,Hiroyoshi Nishikawa,Kohei Shitara
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (18): 2053-2061 被引量:971
标识
DOI:10.1200/jco.19.03296
摘要

PURPOSE: This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS: Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional patients were enrolled in a dose-expansion part. Regorafenib of 80-160 mg was administered once daily for 21 days on/7 days off with nivolumab 3 mg/kg every 2 weeks. The primary end point was dose-limiting toxicity (DLT) during the first 4 weeks to estimate the recommended dose. RESULTS: Fifty patients (25 each with gastric and colorectal cancer) were enrolled. All patients had received ≥ 2 previous lines of chemotherapy, including anti-angiogenetic inhibitors in 96% of patients. Seven patients with gastric cancer had previously been treated with immune checkpoint inhibitors. One patient had microsatellite instability-high colorectal cancer, whereas the remaining patients had microsatellite stable or mismatch repair-proficient tumors. Three DLTs (grade 3 colonic perforation, maculopapular rash, and proteinuria) were observed with regorafenib 160 mg; none were observed with 80 or 120 mg. During the dose-expansion part, regorafenib dose was reduced from 120 to 80 mg because of frequent maculopapular rash. The common grade ≥ 3 treatment-related adverse events were rash (12%), proteinuria (12%), and palmar-plantar erythrodysesthesia (10%). Objective tumor response was observed in 20 patients (40%), including 11 with gastric cancer (44%) and 9 with colorectal cancer (36%). Median progression-free survival was 5.6 and 7.9 months in patients with gastric and colorectal cancer, respectively. CONCLUSION: The combination of regorafenib 80 mg plus nivolumab had a manageable safety profile and encouraging antitumor activity in patients with gastric and colorectal cancer, which warrants additional investigations in larger cohorts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sissiarno发布了新的文献求助10
刚刚
迷人悒发布了新的文献求助10
刚刚
迷人悒发布了新的文献求助10
刚刚
liupipi发布了新的文献求助10
1秒前
迷人悒发布了新的文献求助10
1秒前
torfun发布了新的文献求助10
1秒前
迷人悒发布了新的文献求助10
1秒前
迷人悒发布了新的文献求助10
1秒前
田様的应助被踏实的聪健采纳,获得10
1秒前
sissiarno发布了新的文献求助30
2秒前
sissiarno发布了新的文献求助10
2秒前
heluoyu完成签到,获得积分10
2秒前
sissiarno发布了新的文献求助10
3秒前
sissiarno发布了新的文献求助10
5秒前
sissiarno发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
6秒前
sissiarno发布了新的文献求助30
6秒前
sissiarno发布了新的文献求助30
6秒前
詹詹完成签到,获得积分10
7秒前
8秒前
久怨完成签到,获得积分10
8秒前
8秒前
sissiarno发布了新的文献求助10
9秒前
huahuahua发布了新的文献求助10
9秒前
11秒前
久怨发布了新的文献求助10
11秒前
11秒前
11秒前
sissiarno发布了新的文献求助10
11秒前
11秒前
sissiarno发布了新的文献求助10
11秒前
sissiarno发布了新的文献求助30
12秒前
sissiarno发布了新的文献求助30
12秒前
sissiarno发布了新的文献求助10
13秒前
13秒前
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190026
求助须知:如何正确求助?哪些是违规求助? 9577160
关于积分的说明 21851766
捐赠科研通 7788109
什么是DOI,文献DOI怎么找? 3435873
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482761